About | Free Trial

Last Update

2016-06-13T00:00:00.000Z

This profile was last updated on . .

Is this you? Claim your profile.

Wrong Mary Fitzgerald?

Dr. Mary Fitzgerald F.

Vice President of Respiratory Medicine

Pieris Pharmaceuticals Inc

HQ Phone: (857) 246-8794

Pieris Pharmaceuticals Inc

255 State Street 9Th Floor

Boston, Massachusetts 02109

United States

Company Description

Pieris was founded in 2001 based on the groundbreaking discovery of Anticalin proteins and their potential as therapeutics, which was made at the Technical University of Munich. The company's goal has always been to commercialize this technology both thro... more

Find other employees at this company (16)

Background Information

Employment History

Vice President - Clinical
Pulmagen Therapeutics Limited

Education

BSc
Pharmacology
Bath University

Ph.D.

PhD

Sunderland University

Web References (41 Total References)


Management Team :: Pieris Pharmaceuticals, Inc. (PIRS)

www.pieris.com [cached]

Mary Fitzgerald, Ph.D.

...
Mary Fitzgerald, Ph.D.
Vice President of Respiratory Medicine
Dr. Fitzgerald brings to Pieris more than thirty years of respiratory drug development experience. Prior to joining Pieris, Dr. Fitzgerald, from February 2010 was the Executive Vice President of Respiratory at Pulmagen Therapeutics and from November 2002 to February 2010, Dr. Fitzgerald held various positions at Etiologics, Ltd., formerly Argenta Discovery, most recently as Executive Vice President of Respiratory, where she was responsible for clinical development of inhaled and oral drug candidates for both COPD and asthma. Previously, from 1988 to 2002 Dr. Fitzgerald was employed by Bayer Healthcare, as a Project Leader and later as Head of Pharmacology. Dr. Fitzgerald received her PhD from Sunderland University / Wellcome Laboratories and received her BSc Pharmacology from Bath University.


Management Team :: Pieris Pharmaceuticals, Inc. (PIRS)

ir.pieris.com [cached]

Mary Fitzgerald, Ph.D.

...
Mary Fitzgerald, Ph.D.
Vice President of Respiratory Medicine
Dr. Fitzgerald brings to Pieris more than thirty years of respiratory drug development experience. Prior to joining Pieris, Dr. Fitzgerald, from February 2010 was the Executive Vice President of Respiratory at Pulmagen Therapeutics and from November 2002 to February 2010, Dr. Fitzgerald held various positions at Etiologics, Ltd., formerly Argenta Discovery, most recently as Executive Vice President of Respiratory, where she was responsible for clinical development of inhaled and oral drug candidates for both COPD and asthma. Previously, from 1988 to 2002 Dr. Fitzgerald was employed by Bayer Healthcare, as a Project Leader and later as Head of Pharmacology. Dr. Fitzgerald received her PhD from Sunderland University / Wellcome Laboratories and received her BSc Pharmacology from Bath University.


Pieris Pharmaceuticals, Inc. (PIRS) News

ir.pieris.com [cached]

Named Mary Fitzgerald, Ph.D., Vice President of Respiratory Medicine and project leader for PRS-060

...
Preclinical Data on the IL-4 Receptor Antagonist PRS-060 Presented at the European Respiratory Society Conference; Mary Fitzgerald, Ph.D., to Lead Pieris Respiratory Drug Development Program
...
The Company also announced a key addition to its management team with the appointment of Mary Fitzgerald, PhD, as Vice President of Respiratory Medicine.
...
"The progress with PRS-060, as reported by Professor Anderson, and the addition of Dr. Fitzgerald to our management team, demonstrate both our commitment to development of novel therapeutics for serious illnesses, as well as our ability to attract industry leadership of the highest caliber to advance our pipeline."
...
Mary Fitzgerald brings to Pieris more than thirty years of respiratory drug development. Prior to joining Pieris Dr. Fitzgerald held senior positions at Argenta Discovery and Pulmagen Therapeutics, where she was responsible for clinical development of inhaled and oral drug candidates for both COPD and asthma. Previously, she was employed at Bayer Healthcare for 14 years, most recently as Head of Pharmacology. "I'm excited to lead the development of PRS-060 through IND-enabling studies and into the clinic," noted Dr. Fitzgerald.


Preclinical Data on the IL-4 Receptor ...

www.pieris.com [cached]

Preclinical Data on the IL-4 Receptor Antagonist PRS-060 Presented at the European Respiratory Society Conference; Mary Fitzgerald, Ph.D., to Lead Pieris Respiratory Drug Development Program

...
The Company also announced a key addition to its management team with the appointment of Mary Fitzgerald, PhD, as Vice President of Respiratory Medicine.
...
"The progress with PRS-060, as reported by Professor Anderson, and the addition of Dr. Fitzgerald to our management team, demonstrate both our commitment to development of novel therapeutics for serious illnesses, as well as our ability to attract industry leadership of the highest caliber to advance our pipeline."
...
Mary Fitzgerald brings to Pieris more than thirty years of respiratory drug development. Prior to joining Pieris Dr. Fitzgerald held senior positions at Argenta Discovery and Pulmagen Therapeutics, where she was responsible for clinical development of inhaled and oral drug candidates for both COPD and asthma. Previously, she was employed at Bayer Healthcare for 14 years, most recently as Head of Pharmacology. "I'm excited to lead the development of PRS-060 through IND-enabling studies and into the clinic," noted Dr. Fitzgerald.


Preclinical Data on the IL-4 Receptor ...

ir.pieris.com [cached]

Preclinical Data on the IL-4 Receptor Antagonist PRS-060 Presented at the European Respiratory Society Conference; Mary Fitzgerald, Ph.D., to Lead Pieris Respiratory Drug Development Program

...
The Company also announced a key addition to its management team with the appointment of Mary Fitzgerald, PhD, as Vice President of Respiratory Medicine.
...
"The progress with PRS-060, as reported by Professor Anderson, and the addition of Dr. Fitzgerald to our management team, demonstrate both our commitment to development of novel therapeutics for serious illnesses, as well as our ability to attract industry leadership of the highest caliber to advance our pipeline."
...
Mary Fitzgerald brings to Pieris more than thirty years of respiratory drug development. Prior to joining Pieris Dr. Fitzgerald held senior positions at Argenta Discovery and Pulmagen Therapeutics, where she was responsible for clinical development of inhaled and oral drug candidates for both COPD and asthma. Previously, she was employed at Bayer Healthcare for 14 years, most recently as Head of Pharmacology. "I'm excited to lead the development of PRS-060 through IND-enabling studies and into the clinic," noted Dr. Fitzgerald.

Similar Profiles

Other People with this Name

Other people with the name Fitzgerald

Daniel Fitzgerald
Fontana Unified School District

William Fitzgerald
General Catalyst Partners

Brian Fitzgerald
O'Rourke Hospitality Marketing LLC

John Fitzgerald
Aurico Metals Inc

Albion Fitzgerald
CohBar, Inc.

Browse ZoomInfo's Business Contact Directory by City

Browse ZoomInfo's
Business People Directory

Browse ZoomInfo's
Advanced Company Directory